S Sherry, E Gustafson. Show Affiliations »
Abstract
Mesh: See more » CatheterizationCerebrovascular Disorders/drug therapyDrug Hypersensitivity/etiologyFever/chemically inducedFibrinolytic Agents/adverse effectsFibrinolytic Agents/therapeutic useHeart Valve ProsthesisHemorrhage/chemically inducedHumansMyocardial Infarction/drug therapyPlasminogen Activators/therapeutic usePulmonary Embolism/drug therapyStreptokinase/therapeutic useThrombophlebitis/drug therapyThrombosis/drug therapyUrokinase-Type Plasminogen Activator/therapeutic use
Substances: See more » Fibrinolytic AgentsStreptokinasePlasminogen ActivatorsUrokinase-Type Plasminogen Activator
Year: 1985 PMID: 3890708 DOI: 10.1146/annurev.pa.25.040185.002213
Source DB: PubMed Journal: Annu Rev Pharmacol Toxicol ISSN: 0362-1642 Impact factor: 13.820